上尿路尿路上皮癌组织中脂肪因子表达与临床病理特征及预后的相关性

doi:10.19723/j.issn.1671-167X.2022.04.005

Abstract

Abstract:

Objective: To investigate the correlation between expression levels of adipokine and clinicopathological features and prognosis of patients with upper tract urothelial carcinoma (UTUC) based on immunohistochemical staining and bioinformatics analysis. Methods: The 8 adipokines in this study included adiponectin (AdipoQ), leptin (LEP), interleukin (IL)-6, IL-10 and their receptors (AdipoR1, AdipoR2, LEPR, IL-6R, IL-10RA, IL-10RB). Tissue samples of patients with UTUC who underwent surgical treatment in Peking University People's Hospital from January 2014 to April 2021 were selected for immunohistochemical staining. Their quantitative gene expression data were calculated by H-Score, and relevant clinical and follow-up data were collected retrospectively. Transcription group sequencing data of UTUC patients in Gene Expression Omnibus database (GSE134292 dataset) were downloaded for comparison. Chi-square test or t-test was used to compare the expression level of adipokine between non-muscle invasive group and muscle invasive group. Univariate and multivariate Cox regression analysis and Kaplan-Meier survival curve were utilized to analyze independent predictors of overall survival (OS), disease-free survival (DFS), intravesical recurrence-free survival (IVRFS) in the both cohorts. The P < 0.05 was considered statistically significant. Results: In the study, 63 tissue samples of the patients with UTUC who underwent surgical treatment in Peking University People's Hospital and 57 UTUC patients in GSE134292 dataset were selected. In immunohistochemical cohort, the expressions of AdipoQ (P=0.003 6), AdipoR1 (P=0.006 5), LEP (P=0.007 7), IL-10 (P=0.006 9), and IL-10RA (P=0.008 9) were statistically higher in muscle invasive group. In GSE134292 cohort, the expressions of AdipoR1 (P=0.000 4), AdipoR2 (P=0.000 4), IL-6 (P=0.005 0), IL-10 (P=0.001 7), and IL-10RA (P=0.008 1) were statistically higher in muscle invasive group. Kaplan-Meier survival curve and multivariate Cox regression analysis showed that high IL-10RA expression was an independent predictive factor of IVRFS (P=0.044, HR=0.996, 95%CI: 0.992-0.998) in immunohistochemical cohort, which was confirmed in GSE134292 cohort (P=0.014, HR=0.515, 95%CI: 0.304-0.873). Conclusion: The expression levels of AdipoQ, AdipoR1, IL-10, and IL-10RA were correlated with tumor stage, suggesting that these adipokines played important roles in tumor progression. IL-10RA was an independent predictor of IVRFS, suggesting that IL-10 and its receptor played a critical role in tumor recurrence.

Key words: Upper tract urothelial carcinoma, Adipokine, Immunohistochemical

CLC Number:

R737.1

Xiang DAI,Fei WANG,Yi-qing DU,Yu-xuan SONG,Tao XU. Correlation between adipokine and clinicopathological features and prognosis in upper tract urothelial carcinoma[J].Journal of Peking University (Health Sciences), 2022, 54(4): 605-614.

Figures/Tables 7

Figure 1

Table 1

Figure 2

Figure 3

Table 2

Univariate and multivariate Cox regression analysis in immunohistochemical cohort"

Items	OS
	Univariate			Multivariate
	P	HR	95%CI	P	HR	95%CI
Age	0.239	2.264	0.581-8.821
Gender	0.847	1.133	0.320-4.018
T stage	0.046	6.669	1.020-54.223
Grade	0.427	2.324	0.291-18.579
Tumor diameter	0.813	0.871	0.278-2.734
Multifocality	0.614	0.670	0.141-3.176
AdipoQ	0.542	0.996	0.985-1.008
AdipoR1	0.342	1.008	0.992-1.024
AdipoR2	0.968	1.000	0.985-1.015
LEP	0.371	0.994	0.982-1.007
IL-6	0.960	0.999	0.977-1.023
IL-6R	0.900	1.001	0.988-1.014
IL-10	0.309	0.986	0.961-1.013
IL-10RA	0.585	1.003	0.993-1.012

Items	DFS
	Univariate			Multivariate
	P	HR	95%CI	P	HR	95%CI
Age	0.063	2.002	0.962-4.167	0.623	1.251	0.512-3.055
Gender	0.265	0.642	0.295-1.398
T stage	0.001	11.048	3.794-32.174	0.001	13.962	3.159-61.710
Grade	0.055	3.237	0.976-10.735	0.453	0.547	0.113-2.647
Tumor diameter	0.034	2.271	1.065-4.842	0.305	1.507	0.688-3.297
Multifocality	0.855	1.079	0.477-2.442
AdipoQ	0.363	1.003	0.997-1.009
AdipoR1	0.044	1.009	1.000-1.017	0.921	1.001	0.989-1.013
AdipoR2	0.477	1.004	0.994-1.014
LEP	0.223	1.004	0.998-1.010
IL-6	0.135	1.009	0.997-1.020
IL-6R	0.879	1.001	0.993-1.009
IL-10	0.194	1.008	0.996-1.020
IL-10RA	0.073	0.996	0.991-1.000	0.538	1.002	0.996-1.008

Items	IVRFS
	Univariate			Multivariate
	P	HR	95%CI	P	HR	95%CI
Age	0.084	1.038	0.995-1.082	0.586	1.277	0.529-3.083
Gender	0.258	0.622	0.273-1.415
T stage	0.001	45.300	6.093-336.812	0.001	14.418	3.292-63.149
Grade	0.043	4.451	1.048-18.898	0.453	0.545	0.112-2.655
Tumor diameter	0.009	3.054	1.319-7.069	0.307	1.504	0.688-3.288
Multifocality	0.554	1.287	0.558-2.964
AdipoQ	0.154	1.005	0.998-1.011
AdipoR1	0.056	1.009	1.000-1.018	0.975	1.000	0.989-1.010
AdipoR2	0.422	1.004	0.994-1.015
LEP	0.115	1.005	0.999-1.011
IL-6	0.283	1.007	0.995-1.019
IL-6R	0.945	1.000	0.991-1.008
IL-10	0.098	1.010	0.998-1.022	0.863	1.002	0.998-1.004
IL-10RA	0.017	0.994	0.989-0.999	0.044	0.996	0.992-0.998

Table 2

Table 3

Univariate and multivariate Cox regression analysis in GSE134292 cohort"

Items	OS
	Univariate			Multivariate
	P	HR	95%CI	P	HR	95%CI
Age	0.723	1.008	0.966-1.052
Gender	0.830	1.108	0.434-2.829
T stage	0.004	6.108	1.766-21.119	0.043	4.330	1.047-17.905
Grade	0.222	27.340	0.134-5559.469
Tumor location	0.614	1.329	0.440-4.016
AdipoQ	0.450	1.905	0.358-10.137
AdipoR1	0.025	2.077	1.096-3.935	0.713	1.276	0.348-4.681
AdipoR2	0.011	1.950	1.169-3.253	0.915	1.066	0.330-3.449
LEP	0.522	1.338	0.548-3.267
IL-6	0.014	1.359	1.065-1.734	0.417	1.203	0.770-1.878
IL-6R	0.995	0.999	0.632-1.577
IL-10	0.545	1.390	0.479-4.032
IL-10RA	0.036	1.420	1.023-1.971	0.649	0.889	0.535-1.477

Items	DFS
	Univariate			Multivariate
	P	HR	95%CI	P	HR	95%CI
Age	0.435	0.990	0.964-1.016
Gender	0.408	1.299	0.700-2.411
T stage	0.059	1.814	0.979-3.360	0.189	1.555	0.805-3.005
Grade	0.169	1.720	0.795-3.721
Tumor location	0.124	1.873	0.841-4.168
AdipoQ	0.667	1.341	0.352-5.101
AdipoR1	0.077	1.499	0.957-2.350	0.345	1.264	0.777-2.056
AdipoR2	0.126	1.355	0.918-2.000
LEP	0.086	1.652	0.932-2.928	0.318	1.384	0.731-2.622
IL-6	0.659	1.044	0.864-1.261
IL-6R	0.619	1.070	0.820-1.396
IL-10	0.311	1.529	0.672-3.475
IL-10RA	0.315	1.157	0.871-1.539

Items	IVRFS
	Univariate			Multivariate
	P	HR	95%CI	P	HR	95%CI
Age	0.133	0.977	0.948-1.007
Gender	0.829	1.085	0.516-2.283
T stage	0.536	0.797	0.388-1.638
Grade	0.870	0.934	0.414-2.109
Tumor location	0.015	3.049	1.245-7.464	0.046	2.491	1.014-6.115
AdipoQ	0.239	0.026	0.001-11.313
AdipoR1	0.935	1.019	0.646-1.607
AdipoR2	0.490	0.847	0.529-1.357
LEP	0.317	0.499	0.128-1.947
IL-6	0.119	0.795	0.595-1.061
IL-6R	0.137	0.751	0.515-1.095
IL-10	0.067	0.279	0.071-1.093	0.720	1.397	0.225-8.694
IL-10RA	0.008	0.496	0.294-0.836	0.014	0.515	0.304-0.873

Table 3

Figure 4

References 24

1	Siegel RL , Miller KD , Jemal A . Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69 (1): 7- 34. doi: 10.3322/caac.21551
2	黄健. 中国泌尿外科和男科疾病诊断治疗指南(2019版)[M]. 北京: 科学出版社, 2019.
3	Rouprêt M , Babjuk M , Burger M , et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2020 Update[J]. Eur Urol, 2021, 79 (1): 62- 79. doi: 10.1016/j.eururo.2020.05.042
4	Polito R , Nigro E , Fei L , et al. Adiponectin is inversely associa-ted with tumour grade in colorectal cancer patients[J]. Anticancer Res, 2020, 40 (7): 3751- 3757. doi: 10.21873/anticanres.14364
5	Di Zazzo E , Polito R , Bartollino S , et al. Adiponectin as link factor between adipose tissue and cancer[J]. Int J Mol Sci, 2019, 20 (4): 839. doi: 10.3390/ijms20040839
6	Hebbard L , Ranscht B . Multifaceted roles of adiponectin in cancer[J]. Best Pract Res Clin Endocrinol Metab, 2014, 28 (1): 59- 69. doi: 10.1016/j.beem.2013.11.005
7	Perrier S , Jardé T . Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer[J]. Curr Med Chem, 2012, 19 (32): 5501- 5512. doi: 10.2174/092986712803833137
8	Kashiwagi E , Abe T , Kinoshita F , et al. The role of adipocytokines and their receptors in bladder cancer: Expression of adiponectin or leptin is an independent prognosticator[J]. Am J Transl Res, 2020, 12 (6): 3033- 3045.
9	Park EJ , Lee JH , Yu GY , et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression[J]. Cell, 2010, 140 (2): 197- 208. doi: 10.1016/j.cell.2009.12.052
10	Mannino MH , Zhu Z , Xiao H , et al. The paradoxical role of IL-10 in immunity and cancer[J]. Cancer Letters, 2015, 367 (2): 103- 107. doi: 10.1016/j.canlet.2015.07.009
11	Sato T , Terai M , Tamura Y , et al. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy[J]. Immunol Res, 2011, 51 (2/3): 170- 182.
12	Lippitz BE , Harris RA . Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis[J]. Oncoimmunology, 2016, 5 (5): e1093722. doi: 10.1080/2162402X.2015.1093722
13	Lee YC , Wu WJ , Lin HH , et al. Prognostic value of leptin receptor overexpression in upper tract urothelial carcinomas in Taiwan[J]. Clin Genitourin Cancer, 2017, 15 (4): e653- e659. doi: 10.1016/j.clgc.2017.01.002
14	Holland WL , Miller RA , Wang ZV , et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin[J]. Nat Med, 2011, 17 (1): 55- 63. doi: 10.1038/nm.2277
15	Hebbard LW , Garlatti M , Young LJ , et al. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model[J]. Cancer Res, 2008, 68 (5): 1407- 1416. doi: 10.1158/0008-5472.CAN-07-2953
16	Sun LY , Li XJ , Sun YM , et al. LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1[J]. Mol Cancer, 2018, 17 (1): 127. doi: 10.1186/s12943-018-0879-9
17	Chou SH , Tseleni-Balafouta S , Moon HS , et al. Adiponectin receptor expression in human malignant tissues[J]. Horm Cancer, 2010, 1 (3): 136- 145. doi: 10.1007/s12672-010-0017-7
18	Hsu TI , Wang YC , Hung CY , et al. Positive feedback regulation between IL10 and EGFR promotes lung cancer formation[J]. Oncotarget, 2016, 7 (15): 20840- 20854. doi: 10.18632/oncotarget.7894
19	Qian Q , Wu C , Chen J , et al. Relationship between IL10 and PD-L1 in liver hepatocellular carcinoma tissue and cell lines[J]. Biomed Res Int, 2020, 2020, 8910183.
20	Satyam A , Singh P , Badjatia N , et al. A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder[J]. Urol Oncol, 2011, 29 (1): 58- 65. doi: 10.1016/j.urolonc.2009.06.002
21	Agrawal U , Kumari N , Mishra AK , et al. Immune signature of urothelial cancer associated with grade, recurrence, and invasion[J]. Urol Oncol, 2016, 34 (9): 418.
22	Cai T , Mazzoli S , Meacci F , et al. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma[J]. J Urol, 2007, 178 (5): 1906- 1912. doi: 10.1016/j.juro.2007.07.041
23	Rabinovich A , Medina L , Piura B , et al. Expression of IL-10 in human normal and cancerous ovarian tissues and cells[J]. Eur Cytokine Netw, 2010, 21 (2): 122- 128.
24	Ramos-Ramírez P , Malmhäll C , Tliba O , et al. Adiponectin/adipoR1 axis promotes IL-10 release by human regulatory T cells[J]. Front Immunol, 2021, 12, 677550. doi: 10.3389/fimmu.2021.677550

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	. [J]. Journal of Peking University(Health Sciences), 2001, 33(2): 181 -182 .
[2]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(6): 663 -665 .
[3]	. [J]. Journal of Peking University(Health Sciences), 2008, 40(1): 39 -42 .
[4]	. [J]. Journal of Peking University(Health Sciences), 2008, 40(5): 551 -554 .
[5]	. [J]. Journal of Peking University(Health Sciences), 2003, 35(3): 307 -310 .
[6]	. [J]. Journal of Peking University(Health Sciences), 2002, 34(1): 64 -67 .
[7]	. [J]. Journal of Peking University(Health Sciences), 2001, 33(5): 457 -461 .
[8]	. [J]. Journal of Peking University(Health Sciences), 2008, 40(4): 369 -373 .
[9]	. [J]. Journal of Peking University(Health Sciences), 2010, 42(2): 126 -130 .
[10]	. [J]. Journal of Peking University(Health Sciences), 2003, 35(5): 499 -502 .

Items		IHC cohort	GSE134292 cohort	P value
Number		63	57
Age/years		68.25±9.26	68.58±10.45	0.858
Gender	Male	38 (60.3)	37 (64.9)	0.607
	Female	25 (39.7)	20 (35.1)
T stage	T_a-T₁	35 (55.6)	26 (45.6)	0.281
	T₂-T₄	28 (44.4)	31 (54.4)
Grade	Low-grade	15 (23.8)	12 (21.1)	0.721
	High-grade	48 (76.2)	45 (78.9)

Correlation between adipokine and clinicopathological features and prognosis in upper tract urothelial carcinoma

RICH HTML

PDF (PC)

Abstract

Cite this article

share this article

Figures/Tables 7

References 24

Related Articles 4

Metrics

Comments

Recommended 10

[1]	Zhi-hua LI,Chun-ru XU,Yin LIU,Hua GUAN,Meng ZHANG,Xin-yan CHE,Qi TANG,Yan-bo HUANG,Xue-song LI,Li-qun HOU. Correlation between daily fluid intake behavioral habits and pathological characteristics of upper tract urothelial carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 621-627.
[2]	Bao GUAN,Mai WENG,Hang FAN,Ding PENG,Dong FANG,Geng-yan XIONG,Xue-song LI,Li-qun ZHOU. Evaluating the impact of preoperative anemia on the prognosis of upper tract urothelial carcinoma following radical nephroureterectomy: A single-center retrospective study of 686 patients [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1056-1061.
[3]	Run-zhuo MA,Hai-zhui XIA,Min LU,Zhi-ying ZHANG,Qi-ming ZHANG,Jian LU,Guo-liang WANG,Lu-lin MA. Impact of diagnostic ureteroscopy and biopsy on radical nephroureterectomy of upper tract urothelial carcinoma [J]. Journal of Peking University(Health Sciences), 2019, 51(4): 665-672.
[4]	GUAN Bao, CAO Zhen-peng, PENG Ding, LI Yi-fan, ZHAN Yong-hao, LIU Li-bo, HE Shi-ming, XIONG Geng-yan, LI Xue-song, ZHOU Li-qun. Prognostic factors of patients with T2N0M0 upper tract urothelial carcinoma: a single-center retrospective study of 235 patients [J]. Journal of Peking University(Health Sciences), 2017, 49(4): 603-607.